Sarepta Therapeutics Reveals Priority Review Voucher Sale in $102M Deal

Published on: 

Company to invest proceeds in further R&D efforts.

Sarepta Therapeutics, a medical research and drug development company, has announced the sale of its rare disease Priority Review Voucher (PRV), receiving $102 upon completion of the sale. According to the company, it plans on using the money earned from the sale towards continued R&D efforts, supporting the development of more transformative therapies.


Following the FDA’s accelerated approval of Elevidys for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD), Sarepta was awarded the PRV. The program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

Reference: Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million. Sarepta. July 5, 2023. Accessed July 7, 2023.